抗凝药与老年严重创伤患者死亡率和功能结局的关联
这项基于维多利亚州创伤登记库的人群登记研究纳入2017年7月至2018年6月65岁及以上严重创伤患者1323例,其中249例(18.8%)使用抗凝药、380例(28.7%)使用抗血小板药、694例(52.5%)未使用。多因素logistic回归显示,使用抗凝药与院内死亡风险升高相关(AOR 2.38,95%CI 1.58–3.59),但6个月GOS-E在抗凝药、抗血小板药与未使用抗凝药者间无差异(抗凝药AOR 0.71,95%CI 0.48–1.05;抗血小板药AOR 1.02,95%CI 0.73–1.42)。作者认为应准确询问抗凝药使用史及适应证,并立即启动逆转治疗。
要点
- 65岁及以上严重创伤患者伤时使用抗凝药与院内死亡率升高相关(AOR 2.38,95%CI 1.58–3.59)。
- 抗凝药、抗血小板药与未使用抗凝药者6个月GOS-E无差异(抗凝药AOR 0.71,95%CI 0.48–1.05;抗血小板药AOR 1.02,95%CI 0.73–1.42)。
- 作者认为应准确询问抗凝药使用史及其适应证,并立即启动逆转治疗。
- 1323例中249例(18.8%)使用抗凝药(其中8例同时使用抗凝药和抗血小板药),380例(28.7%)使用抗血小板药,694例(52.5%)未使用。
适用人群与场景
- 65岁及以上严重创伤患者,数据来自2017年7月至2018年6月维多利亚州创伤登记库。
研究设计与关键结果
- 研究类型:基于人群的登记研究;纳入1323例65岁及以上严重创伤患者,249例(18.8%)使用抗凝药(其中8例同时使用抗凝药和抗血小板药),380例(28.7%)使用抗血小板药,694例(52.5%)未使用。
- 院内死亡:使用抗凝药者较未使用抗凝药者院内死亡比值升高(AOR 2.38,95%CI 1.58–3.59)。
- 6个月GOS-E:抗凝药使用、抗血小板药使用与未使用抗凝药者间无差异(抗凝药AOR 0.71,95%CI 0.48–1.05;抗血小板药AOR 1.02,95%CI 0.73–1.42)。
证据类型、等级与局限
- 证据类型:基于人群的登记研究,使用多因素logistic回归校正已知混杂因素。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,这些发现说明应准确询问抗凝药使用史及其适应证,并立即启动逆转治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The number of trauma patients taking anticoagulants and antiplatelet agents is increasing as society ages. However, there have been limited and inconsistent reports of the association between anticoagulants and mortality and functional outcomes. This study aimed to quantify the association between anticoagulant/antiplatelet medication at the time of injury and both short-term and longer-term outcomes in older major trauma patients.
METHODS: This was a population-based registry study using data from the Victorian State Trauma Registry from July 2017 to June 2018. We included patients with major trauma aged 65 years and older. The outcomes of interest were in-hospital mortality, hospital length of stay, intensive care unit length of stay and the Extended Glasgow Outcome Scale (GOS-E) at 6 months after injury. We examined the association between the outcomes and anticoagulants/antiplatelet agents at the time of injury and used multivariable logistic regression models to account for known confounders.
RESULTS: There were 1323 older adults eligible for inclusion in the study, of which 249 (18.8%) were taking anticoagulants (n=8 were taking both anticoagulants and antiplatelet agents), 380 (28.7%) were taking antiplatelet agents and 694 (52.5%) were not using either. Any anticoagulant use was associated with higher odds of in-hospital mortality (adjusted OR (AOR), 2.38; 95% CI 1.58 to 3.59) compared with not using anticoagulants. No differences were observed in the GOS-E at 6 months after injury between any anticoagulants use, antiplatelet use and no anticoagulant use (anticoagulant AOR, 0.71; 95% CI 0.48 to 1.05, antiplatelet AOR, 1.02; 95% CI 0.73 to 1.42).
CONCLUSION: Anticoagulant use at the time of injury was associated with higher odds of in-hospital mortality but did not adversely impact functional outcomes at 6 months after injury. These findings demonstrate the importance of seeking an accurate history of anticoagulant use and its indication, as well as the immediate initiation of reversal therapies.
参考来源
- Sato N, Cameron P, Mclellan S, et al. Association between anticoagulants and mortality and functional outcomes in older patients with major trauma. Emerg Med J. 2021. PMID: 34610958. doi:10.1136/emermed-2019-209368
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。